Growing MSK Costs
Acute and chronic MSK conditions are rapidly growing cost areas with limited preventative care focus in the U.S. healthcare system.
Legal Notice
Certain information set forth in this presentation contains "forward-looking information", including, but not limited to, "potential penetration statements" and "assumptions", under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, all information contained herein constitutes forward-looking statements and includes, but is not limited to, the expected development of MMH's business.
These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.
There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. MMH undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change. The reader is cautioned not to place reliance on forward-looking statements.
MMH makes no representation or warranty to any prospective investor with respect to the forward-looking statements. With respect to these statements made available by or on behalf of MMH to prospective investors, each prospective investor acknowledges that: (a) there are uncertainties inherent in attempting to make such statements, (b) such investor is familiar with such uncertainties, (c) such investor takes full responsibility for making its own evaluation of the adequacy and accuracy of all information provided, and (d) prospective investors shall have no claim against MMH, including its officers, directors and legal and financial representatives, whatsoever based upon the inaccuracy of any information contained in this document.
Market Need
Acute and chronic MSK conditions are rapidly growing cost areas with limited preventative care focus in the U.S. healthcare system.
Lack of comprehensive risk screening, fragmented data/systems, and high-cost specialty care interventions after the patient is injured.
Direct barrier to optimal athletic performance and military readiness. High-cost interventions after injuries occur.
The Challenge
Acute and chronic MSK conditions are rapidly growing cost areas
Limited preventative care focus in the U.S. health care system
Lack of comprehensive risk screening, fragmented data/systems
High-cost, specialty care interventions after the patient is injured
Direct barrier to optimal athletic performance & military readiness
Our Answer
MMH created a novel and automated MSK assessment technology
Combines comprehensive virtual data collection with cutting-edge analytical AI
Removed administrative and data integration barriers impeding optimized preventive care and personalized interventions
Platform poised to scale; no regulatory approval risk impeding GTM adoption
Technology
Methodology
Intellectual Property
Market Opportunity
One Trillion Dollars
Performance optimization, injury prevention. 2.6B registered athletes globally. $40 billion spent annually by parents.
Clinical assessments, early interventions. 3,300 retail clinics. 229,000 primary care. 300,000 MSK specialty providers.
Field readiness, injury mitigation. 10 million lives in military (1.8M active, 12.2M veterans).
Cost control, workplace wellness. 300 million lives. 100 million MSK patients.
Revenue Potential
Consumer Athletics/Youth Sports — 0.5% Penetration: 2.6B registered participants @$35 per assessment = $455,000,000
DOD/SOCOM/VA TAMPA — 100% Penetration: Human Performance @$35 per assessment = $126,000,000 (2 assessments per year)
Providers — 1% Penetration: 30,000 MSK and 2,900 Primary Care @$35 per assessment = $690,000,000 per year (600 assessments per provider per year)
Health Plans — 1% Penetration: One million patients @$300 per year = $300,000,000
Market Validation
The musculoskeletal (MSK) health market has proven to be one of the fastest-growing sectors in digital health, with several platforms reaching multi-billion-dollar valuations.
While many companies in this space focus on high-barrier channels such as insurers and large employers, MyMedicalHub (MMH) takes a unique approach — proving value first through direct-to-consumer, athlete, and veteran populations.
Our AI-driven assessments, longitudinal health tracking, and digital therapeutics can be accessed from any smart device — empowering users, providers, and institutions to make more informed decisions and drive better outcomes.
MMH's ability to scale across B2C, B2B, and government channels simultaneously — supported by patented technology and a modular architecture — positions the platform for rapid adoption and long-term impact.
Leadership
Vice Admiral and former CEO Defense Health Agency
Former Regional Medical Director Blue Shield of California
Former COO National Basketball Association
Former CEO HMS
Co-Founder/Executive VP General Counsel of Americhoice (Acquired by UHG)
Former CEO Envision Rx (acquired by RiteAid)
Associate Dean and Professor Dell Medical School, double board-certified in orthopedic surgery and psychiatry
Assistant Professor of Kinesiology and Health Sciences, Chair of Department, Morehouse College
Contact us to learn about investment opportunities and how MyMedicalHub is transforming the musculoskeletal healthcare market.
Contact Us